Literature DB >> 16899062

N-Arachidonyl-glycine inhibits the glycine transporter, GLYT2a.

Amy L Wiles1, Rhonda-Jo Pearlman, Mari Rosvall, Karin R Aubrey, Robert J Vandenberg.   

Abstract

N-arachidonyl-glycine is one of a series of N-arachidonyl-amino acids that are derived from arachidonic acid. N-arachidonyl-glycine is produced in a wide range of tissues with greatest abundance in the spinal cord. Here we report that N-arachidonyl-glycine is a reversible and non-competitive inhibitor of glycine transport by GLYT2a, but has little effect on glycine transport by GLYT1b or gamma-amino butyric acid transport by GAT1. It has previously been reported that the activity of GLYT2a is down-regulated by protein kinase C and therefore we investigated whether the actions of N-arachidonyl-glycine on GLYT2a are mediated by second messenger systems that lead to the activation of protein kinase C. However, the protein kinase C inhibitor, staurosporine, had no effect on the actions of N-arachidonyl-glycine on GLYT2a. Thus, the actions of N-arachidonyl-glycine are likely to be mediated by a direct interaction with the transporter. We have further defined the pharmacophore by investigating the actions of other N-arachidonyl amino acids as well as the closely related compounds arachidonic acid, anandamide and R1-methanandamide. Arachidonic acid, anandamide and R1-methanandamide have no effect on glycine transport, but N-arachidonyl-l-alanine has similar efficacy at GLYT2a to N-arachidonyl-glycine, and N-arachidonyl-gamma-amino butyric acid is less efficacious. These observations define a novel recognition site for the N-arachidonyl amino acids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16899062     DOI: 10.1111/j.1471-4159.2006.04107.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  37 in total

Review 1.  The solute carrier 6 family of transporters.

Authors:  Stefan Bröer; Ulrik Gether
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 2.  N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets.

Authors:  Mark Connor; Chris W Vaughan; Robert J Vandenberg
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

3.  Discovery of GlyT2 Inhibitors Using Structure-Based Pharmacophore Screening and Selectivity Studies by FEP+ Calculations.

Authors:  Filip Fratev; Manuel Miranda-Arango; Ashley Bryan Lopez; Elvia Padilla; Suman Sirimulla
Journal:  ACS Med Chem Lett       Date:  2019-05-22       Impact factor: 4.345

Review 4.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

Review 5.  A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development.

Authors:  Hee-Yong Kim; Arthur A Spector; Zheng-Mei Xiong
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-07-23       Impact factor: 3.072

6.  So what do we call GPR18 now?

Authors:  S P H Alexander
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 7.  Biosynthesis, degradation and pharmacological importance of the fatty acid amides.

Authors:  Emma K Farrell; David J Merkler
Journal:  Drug Discov Today       Date:  2008-04-03       Impact factor: 7.851

Review 8.  Cannabinoid receptors: nomenclature and pharmacological principles.

Authors:  Linda Console-Bram; Jahan Marcu; Mary E Abood
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-28       Impact factor: 5.067

9.  Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT.

Authors:  Andrew J Gilmore; Marika Heblinski; Aaron Reynolds; Michael Kassiou; Mark Connor
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

10.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.